P588: Ustekinumab for the treatment of Crohn's disease patients with TNF antagonist induced psoriasis. Real life experience from a tertiary referral center through week 54ECCO '17 Barcelona
2017
P589: Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysisECCO '17 Barcelona
2017
P590: Reasons for discontinuation and switch of biologic therapy in IBD: findings from a large international observational study (03)ECCO '17 Barcelona
2017
P591: Therapeutic drug monitoring in Paediatric inflammatory bowel disease on maintenance infliximab and adalimumab treatment improves clinical remission with a proactive approachECCO '17 Barcelona
2017
P592: Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohortECCO '17 Barcelona
2017
P593: Hospital resource use and cost associated with first-line anti-TNF therapy in patients with IBD in the UK: comparison of subcutaneous (adalimumab) and intravenous (infliximab) therapiesECCO '17 Barcelona
2017
P594: Ustekinumab treatment effectiveness in clinical practice – a multicentre retrospective review of long-term outcomes in Crohn's diseaseECCO '17 Barcelona
2017
P596: FMT in patients with steroid dependant ulcerative colitis a single centre observational studyECCO '17 Barcelona
2017
P598: Mucosal and transmural healing during anti-TNF therapy. Is fecal calprotectin a marker of therapeutic response?ECCO '17 Barcelona
2017
P599: Home testing for faecal calprotectin: follow-up results from the first UK trialECCO '17 Barcelona
2017
P600: Infliximab trough levels for remission induction and long term therapy management of inflammatory bowel diseaseECCO '17 Barcelona
2017
P601: Can Amitriptylin improve the quality of life in patients with Crohn's disease?ECCO '17 Barcelona
2017
P602: Clinical/biochemical predictors of response to anti-TNFa therapies in a tertiary referral centreECCO '17 Barcelona
2017
P603: Hospitalisation risk and reintervention after ileocolonic resection with anastomosis in patients with Crohn's disease. Results from the PRACTICROHN studyECCO '17 Barcelona
2017
P604: Usefulness of stool hemoglobin and fecal calprotectin for detecting of mild to moderate ulcerative colitisECCO '17 Barcelona
2017
P605: Rapid detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the reference biologic or the biosimilar CT-P13: performance comparison with ELISAECCO '17 Barcelona
2017